Study Information

Title: Adcetris (Brentuximab Vedotin), Combination Chemotherapy, and Radiation Therapy in Treating Younger Patients With Stage IIB, IIIB and IV Hodgkin Lymphoma External
Status: Recruiting participants
Conditions: Stage II Childhood Hodgkin Lymphoma; Stage III Childhood Hodgkin Lymphoma; Stage IV Childhood Hodgkin Lymphoma
Interventions: Drug: brentuximab vedotin; Drug: etoposide; Drug: prednisone; Drug: doxorubicin; Drug: cyclophosphamide; Drug: Dacarbazine(R); Drug: filgrastim; Procedure: quality of life assessment; Radiation: radiation therapy
Institutions: Dana-Farber Cancer Institute, Massachusetts General Hospital
Health Topics: Hodgkin Lymphoma

Contact Information


Dana-Farber Harvard Cancer Center
Boston, MA 02115
Amy Billett, MD
617-632-5640
amy_billett@dfci.harvard.edu
Massachusetts General Hospital Cancer Center
Boston, MA 02114
Alison Friedmann, MD
617-726-2737
afriedmann@partners.org